JPRN-UMIN000008590招募中2 期
Phase II study of daily administration of TS-1 plus lentinan(LNT) in advanced or recurrent gastric cancer. - Phase II study of daily administration of TS-1 plus lentinan(LNT) in advanced or recurrent gastric cancer.
Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2012年8月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Limitation of use of TS-1. 2) Infection and inflammation. 3) Serious heart disease. 4) Symptomatic pulmonary fibrosis or interstitial pneumonia. 5) Severe complications, such as ileus, uncontrolled diabetes mellitus, heart failure, renal failure and hepatocirrhosis. 6) A large amount of pleural effusion or peritoneal fluid. 7) Widespread bone-marrow metastases. 8) Brain metastasis. 9) Fresh bleeding from digestive organs. 10) Diarrhea. 11) Severe mental disorders. 12) Active synchronous malignancy. 13) Patients under treatment with flucytosine, phenytoin or warfarin potassium. 14) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy. 15) Other patients who are unfit for the study as determined by the attending physician.
研究者
相似试验
已完成
2 期
Randomized phase II study of dose schedule of TS-1 for resected Colorectal CancerStage III colorectal cancerJPRN-UMIN000013185Clinical Study Group of Osaka (CSGO), Colorectal Cancer Treatment Group170
已完成
2 期
Phase II Study of TS-1 with Patient-Reported Outcome(PRO) Evaluation in Elderly Patients with Advanced NSCLCon-small cell lung cancerJPRN-UMIN000002035Department of Respiratory Medicine & Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School40
招募中
不适用
A PhaseII Study of Dose Schedule of TS-1 for Metastatic/Advanced Breast CancerMetastatic/Advanced Breast CancerJPRN-UMIN000008879Wakayama Medical University, Department of Thoracic and Cardiovascular Surgery40
已完成
2 期
A Randomized Phase II Study of Dose Schedule of TS-1 for Metastatic/Advanced Pancreatic CancerMetastatic/Locally Advanced Pancreatic CancerJPRN-UMIN000008604Wakayama Medical University190
进行中（未招募）
不适用
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDsevere sepsisMedDRA version: 8.1Level: LLTClassification code 10040047Term: SepsisEUCTR2006-002112-99-BEEli Lilly & Company Limited488